Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been given a consensus rating of “Moderate Buy” by the eighteen brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $37.27.

DNLI has been the topic of several research reports. Robert W. Baird initiated coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price on the stock. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. HC Wainwright raised their target price on Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Friday, February 28th. B. Riley restated a “buy” rating and issued a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday. Finally, Morgan Stanley initiated coverage on Denali Therapeutics in a research report on Friday. They issued an “overweight” rating and a $33.00 target price on the stock.

Insider Buying and Selling

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now owns 260,721 shares of the company’s stock, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the sale, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC increased its stake in Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. Quest Partners LLC acquired a new stake in Denali Therapeutics during the third quarter worth $73,000. GF Fund Management CO. LTD. acquired a new stake in shares of Denali Therapeutics in the fourth quarter valued at $62,000. Point72 Hong Kong Ltd acquired a new stake in shares of Denali Therapeutics in the fourth quarter valued at $65,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after buying an additional 885 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Trading Up 2.6 %

Shares of DNLI opened at $16.69 on Friday. Denali Therapeutics has a 12 month low of $14.01 and a 12 month high of $33.33. The stock’s 50 day moving average is $20.88 and its two-hundred day moving average is $24.35. The firm has a market cap of $2.40 billion, a P/E ratio of -6.05 and a beta of 1.43.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08. Equities research analysts forecast that Denali Therapeutics will post -2.71 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.